亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

An Effective Anti-Cancer Combination Therapy, with Substantially Reduced Side Effects

技術應用

Anti-cancer combination therapy

詳細技術說明

Researchers at the University of California, Davis have developed an effective local therapeutic strategy with substantially reduced side effects using a combination of doxorubicin (Dox) and copper (II). Cu-liposomes were loaded with Dox up to a maximum concentration of 0.6mg-drug/mg-lipid. UC Davis researchers have studied the efficacy of Cu-Dox liposomes and optimized the treatment strategy using the highly invasive and metastatic Met-1 tumor, a syngeneic model of human breast carcinoma. All animals receiving the combined therapy survived throughout the 28 day course of treatment and did not show any side effects. Significant tumor regression was accomplished by combining Cu-Dox liposomes with another drug and tumor insonation.

附加資料

Patent Number: WO2011109334A3
Application Number: WO2011US26592A
Inventor: FERRARA, Katherine, W. | KHEIROLOMOOM, Azadeh
Priority Date: 1 Mar 2010
Priority Number: WO2011109334A3
Application Date: 1 Mar 2011
Publication Date: 1 Mar 2012
IPC Current: A61K0009127 | A61K00317042 | A61K003300 | A61K004748 | A61P003500
Assignee Applicant: The Regents of the University of California
Title: LOCALIZATION OF AGENTS AT A TARGET SITE WITH A COMPOSITION AND AN ENERGY SOURCE | LOCALISATION D'AGENTS DANS UN SITE CIBLE COMPORTANT UNE COMPOSITION ET UNE SOURCE D'ÉNERGIE
Usefulness: LOCALIZATION OF AGENTS AT A TARGET SITE WITH A COMPOSITION AND AN ENERGY SOURCE | LOCALISATION D'AGENTS DANS UN SITE CIBLE COMPORTANT UNE COMPOSITION ET UNE SOURCE D'ÉNERGIE
Summary: For localized delivery of an agent to a target site for treating tumor (claimed); for treating other diseases e.g. diabetes, infection, inflammation, cardiovascular diseases including ischemic conditions, cardiopathies, and brain diseases, coronary artery disease (CAD); atherosclerosis; thrombosis; restenosis; vasculitis including autoimmune and viral vasculitis such as polyarteritis nodosa, Churg-Strauss syndrome, Takayasu's arteritis, Kawasaki disease and Rickettsial vasculitis; atherosclerotic aneurisms; myocardial hypertrophy; congenital heart diseases (CHD); ischemic heart disease and anginas; acquired valvular/endocardial diseases; primary myocardial diseases including myocarditis; arrhythmias; and transplant rejection.
Novelty: Localized delivery of an agent to a target site for treating e.g. tumor involves administering a composition comprising agent-transition metal complex to subject having target site; and irradiating target site with energy source